Physician profile
Christopher M Logas
NPI 1780140640
$15,873.31
in general payments reported to CMS, 2019-2025
24 companies · $7,338 in 2025
The $7,338 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $200 · 2023: $2,094 · 2024: $6,242 · 2025: $7,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $1,650 · Education: $299 · Travel and Lodging: $25.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,699.29 |
| Consulting Fee | $1,650.00 |
| Education | $299.20 |
| Travel and Lodging | $25.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,314.59 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Dermavant Sciences, INC. | $1,340.99 | 2023-2024 | Vtama |
| Genzyme Corporation | $1,147.00 | 2023-2025 | |
| Amgen INC. | $1,016.35 | 2023-2025 | Otezla, Otezla |
| Abbvie INC. | $918.56 | 2023-2025 | |
| Incyte Corporation | $893.77 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $829.75 | 2023-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $762.28 | 2023-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $758.60 | 2023-2025 | Adbry, Anzupgo |
| Organon LLC | $738.09 | 2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $728.24 | 2023-2025 | Ilumya |
| Lilly USA, LLC | $540.14 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Ucb, INC. | $526.87 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $420.08 | 2023-2025 | |
| Journey Medical Corporation | $415.46 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $330.09 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $322.72 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.90 | 2023-2025 | Spevigo, Cyltezo |
| Almirall LLC | $218.89 | 2025 | Klisyri, Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $184.93 | 2023-2024 | Cabtreo, Siliq, Targretin |
| E.R. Squibb & Sons, L.L.C. | $174.58 | 2023 | Sotyktu |
| Cipher Pharmaceuticals US LLC | $26.87 | 2025 | Spinosad, Natroba |
| Verrica Pharmaceuticals INC. | $22.95 | 2025 | Ycanth |
| Lnhc, INC | $14.61 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Logas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.